Compare CYRX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYRX | ADCT |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | Switzerland |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 484.4M |
| IPO Year | 2008 | 2019 |
| Metric | CYRX | ADCT |
|---|---|---|
| Price | $7.96 | $3.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $12.94 | $7.75 |
| AVG Volume (30 Days) | 425.4K | ★ 750.6K |
| Earning Date | 03-03-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | 30.86 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | $81,357,000.00 |
| Revenue This Year | $10.92 | N/A |
| Revenue Next Year | $8.08 | $68.29 |
| P/E Ratio | $5.86 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $4.63 | $1.05 |
| 52 Week High | $11.45 | $4.98 |
| Indicator | CYRX | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 40.74 |
| Support Level | $6.57 | $3.25 |
| Resistance Level | $8.52 | $3.87 |
| Average True Range (ATR) | 0.39 | 0.27 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 28.43 | 4.63 |
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).